These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 37158855)

  • 1. An analysis of DPV and DIVE registry patients with chronic kidney disease according to the finerenone phase III clinical trial selection criteria.
    Bramlage P; Lanzinger S; Mühldorfer S; Milek K; Gillessen A; Veith R; Ohde T; Danne T; Holl RW; Seufert J
    Cardiovasc Diabetol; 2023 May; 22(1):108. PubMed ID: 37158855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient and disease characteristics of type-2 diabetes patients with or without chronic kidney disease: an analysis of the German DPV and DIVE databases.
    Bramlage P; Lanzinger S; van Mark G; Hess E; Fahrner S; Heyer CHJ; Friebe M; Seufert J; Danne T; Holl RW
    Cardiovasc Diabetol; 2019 Mar; 18(1):33. PubMed ID: 30878037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolution of Mineralocorticoid Receptor Antagonists in the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus.
    Wish JB; Pergola P
    Mayo Clin Proc Innov Qual Outcomes; 2022 Dec; 6(6):536-551. PubMed ID: 36277502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and Diabetes.
    Filippatos G; Anker SD; Pitt B; Rossing P; Joseph A; Kolkhof P; Lambelet M; Lawatscheck R; Bakris GL; Ruilope LM; Agarwal R
    JACC Heart Fail; 2022 Nov; 10(11):860-870. PubMed ID: 36328655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results.
    Agarwal R; Anker SD; Filippatos G; Pitt B; Rossing P; Ruilope LM; Boletis J; Toto R; Umpierrez GE; Wanner C; Wada T; Scott C; Joseph A; Ogbaa I; Roberts L; Scheerer MF; Bakris GL
    Nephrol Dial Transplant; 2022 Jun; 37(7):1261-1269. PubMed ID: 34850173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigating the use of finerenone in children with chronic kidney disease and proteinuria: design of the FIONA and open-label extension studies.
    Schaefer F; Montini G; Kang HG; Walle JV; Zaritsky J; Schreuder MF; Litwin M; Scalise A; Scott H; Potts J; Iveli P; Breitenstein S; Warady BA
    Trials; 2024 Mar; 25(1):203. PubMed ID: 38509517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone.
    Agarwal R; Pitt B; Rossing P; Anker SD; Filippatos G; Ruilope LM; Kovesdy CP; Tuttle K; Vaduganathan M; Wanner C; Bansilal S; Gebel M; Joseph A; Lawatscheck R; Bakris GL
    JAMA Cardiol; 2023 Aug; 8(8):732-741. PubMed ID: 37314801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal function deterioration in adult patients with type-2 diabetes.
    Bramlage P; Lanzinger S; Hess E; Fahrner S; Heyer CHJ; Friebe M; Buschmann I; Danne T; Holl RW; Seufert J
    BMC Nephrol; 2020 Jul; 21(1):312. PubMed ID: 32727401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Diagnosis and Treatment of Diabetic Kidney Disease.
    Rodriguez F; Lee DJ; Gad SS; Santos MP; Beetel RJ; Vasey J; Bailey RA; Patel A; Blais J; Weir MR; Dash R
    Adv Ther; 2021 Aug; 38(8):4425-4441. PubMed ID: 34254257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study.
    Ruilope LM; Pitt B; Anker SD; Rossing P; Kovesdy CP; Pecoits-Filho R; Pergola P; Joseph A; Lage A; Mentenich N; Scheerer MF; Bakris GL
    Nephrol Dial Transplant; 2023 Feb; 38(2):372-383. PubMed ID: 35451488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.
    Agarwal R; Filippatos G; Pitt B; Anker SD; Rossing P; Joseph A; Kolkhof P; Nowack C; Gebel M; Ruilope LM; Bakris GL;
    Eur Heart J; 2022 Feb; 43(6):474-484. PubMed ID: 35023547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial.
    Filippatos G; Anker SD; Agarwal R; Ruilope LM; Rossing P; Bakris GL; Tasto C; Joseph A; Kolkhof P; Lage A; Pitt B;
    Circulation; 2022 Feb; 145(6):437-447. PubMed ID: 34775784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease.
    Lerma E; White WB; Bakris G
    Postgrad Med; 2023 Apr; 135(3):224-233. PubMed ID: 35392754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between albuminuric CKD and diabetic retinopathy in a real-world setting of type 2 diabetes: Findings from No blind study.
    Sasso FC; Pafundi PC; Gelso A; Bono V; Costagliola C; Marfella R; Sardu C; Rinaldi L; Galiero R; Acierno C; Caturano A; de Sio C; De Nicola L; Salvatore T; Nevola R; Adinolfi LE; Minutolo R;
    Nutr Metab Cardiovasc Dis; 2019 Sep; 29(9):923-930. PubMed ID: 31377186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis.
    Filippatos G; Anker SD; August P; Coats AJS; Januzzi JL; Mankovsky B; Rossing P; Ruilope LM; Pitt B; Sarafidis P; Teerlink JR; Kapelios CJ; Gebel M; Brinker M; Joseph A; Lage A; Bakris G; Agarwal R
    Eur Heart J Cardiovasc Pharmacother; 2023 Feb; 9(2):183-191. PubMed ID: 36639130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.
    Pitt B; Filippatos G; Agarwal R; Anker SD; Bakris GL; Rossing P; Joseph A; Kolkhof P; Nowack C; Schloemer P; Ruilope LM;
    N Engl J Med; 2021 Dec; 385(24):2252-2263. PubMed ID: 34449181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can patiromer allow for intensified renin-angiotensin-aldosterone system blockade with losartan and spironolactone leading to decreased albuminuria in patients with chronic kidney disease, albuminuria and hyperkalaemia? An open-label randomised controlled trial: MorphCKD.
    Mårup FH; Peters CD; Christensen JH; Birn H
    BMJ Open; 2022 Feb; 12(2):e057503. PubMed ID: 35190442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prevalence of chronic kidney disease and screening of renal function in type 2 diabetic patients in Finnish primary healthcare.
    Hagnäs M; Sundqvist H; Jokelainen J; Tumminia A; Vinciguerra F; Loreto C; Frittitta L; Russo GT; Mikkola I
    Prim Care Diabetes; 2020 Dec; 14(6):639-644. PubMed ID: 32527663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus.
    Lv R; Xu L; Che L; Liu S; Wang Y; Dong B
    Front Endocrinol (Lausanne); 2023; 14():1125693. PubMed ID: 36860374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality of care in patients with diabetic kidney disease in Asia: The Joint Asia Diabetes Evaluation (JADE) Registry.
    Luk AO; Li X; Zhang Y; Guo X; Jia W; Li W; Weng J; Yang W; Chan WB; Ozaki R; Tsang CC; Mukhopadhyay M; Ojha AK; Hong EG; Yoon KH; Sobrepena L; Toledo RM; Duran M; Sheu W; Q Do T; Nguyen TK; Ma RC; Kong AP; Chow CC; Tong PC; So WY; Chan JC;
    Diabet Med; 2016 Sep; 33(9):1230-9. PubMed ID: 26511783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.